Tevogen Inc.
Tevogen Inc. is a U.S.-based biotechnology company developing immunotherapies for infectious diseases, cancer, and neurological disorders. Its pipeline includes TVGN 489, the ExacTcell technology platform, and Tevogen.AI, supported by research, preclinical, and clinical development capabilities.
Fiscal year 2025 · change from previous year
Development 2021–2025
Business
Share of revenueLead T-cell therapy candidate being developed for COVID-19 and Long COVID.
Technology platform intended to support targeted cellular immunotherapy development.
Artificial-intelligence initiative supporting drug discovery and product development.
Preclinical immunotherapy candidates addressing cancer and neurological disorders.
Customers
Tevogen currently has no product customers because its candidates have not received marketing approval and the company has not generated product revenue. Potential customers include patients, healthcare providers, specialty pharmacies, payers, and government or institutional healthcare systems that could use or reimburse approved immunotherapies.
Potential recipients of TVGN 489 for COVID-19 and Long COVID if approved.
Potential users of future ExacTcell-enabled or other immunotherapy candidates.
Specialists and hospitals that could prescribe or administer approved therapies.
Insurers and institutional buyers that could determine therapy access and reimbursement.
CROs and investigative sites providing clinical and preclinical development services.
Strategy
Tevogen's strategy is centered on advancing TVGN 489 through clinical development while building additional immunotherapy candidates with ExacTcell and Tevogen.AI. The company is also developing research, manufacturing, and commercialization capabilities so it can support potential product launches if regulatory approvals are obtained. This asset-light, pipeline-driven model seeks to convert proprietary technology and clinical evidence into future therapy products.
Clinical progress is the main pathway toward regulatory approval and future revenue.
Additional candidates can diversify the company beyond a single lead program.
AI-supported discovery may improve candidate selection and development efficiency.
Approved therapies require scalable production, market access, and distribution.
Geography
Tevogen's operations are based in the United States, with research and laboratory activities consolidated at a facility in Warren, New Jersey. The company previously operated a laboratory in Philadelphia, Pennsylvania, and its U.S. base supports clinical development, laboratory research, intellectual-property management, and future commercialization planning.
Risks
Tevogen is a pre-revenue biotechnology company exposed to clinical, regulatory, financing, manufacturing, and commercialization risks because its business depends on obtaining approval for future product candidates. The company states that substantial additional financing is required, while failure to meet Nasdaq listing requirements could impair access to public capital and reduce trading liquidity. Technology, intellectual-property, competitive, and healthcare-policy risks could also reduce the commercial value of its pipeline.
- Clinical and regulatory failureImpact: CriticalLikelihood: High
TVGN 489 and future candidates require successful trials and regulatory authorization before commercialization.
Exposure: TVGN 489 and broader immunotherapy pipeline
- Dependence on additional financingImpact: CriticalLikelihood: High
The company expects substantial funding needs for clinical development, AI initiatives, manufacturing, and commercialization.
Exposure: Operating runway and future development programs
- Nasdaq listing complianceImpact: HighLikelihood: High
Failure to meet minimum bid-price or market-value requirements could result in delisting and reduced financing access.
Exposure: Common stock and public warrants
- Manufacturing and supply executionImpact: HighLikelihood: Low
Cellular immunotherapies require specialized processes, facilities, quality controls, and reliable inputs.
Exposure: Future commercial production
- Technology and intellectual-property riskImpact: HighLikelihood: Low
The value of ExacTcell, Tevogen.AI, and product candidates depends on protecting and validating proprietary technology.
Exposure: Pipeline differentiation and licensing potential
- Commercial adoption and reimbursementImpact: High
Approved therapies may face payer restrictions, provider adoption barriers, competition, or unfavorable pricing.
Exposure: Future product revenue
Accounting
Judgemental itemsThe company has not generated product revenue and expects revenue only after regulatory approval and commercialization.
Impact: Reported results remain focused on operating expenses and financing activity.
Clinical trials, preclinical studies, CRO fees, laboratory supplies, and research personnel costs are generally expensed as incurred.
Impact: Trial timing and program activity can cause significant quarterly expense changes.
The company estimates fair values for common stock and convertible promissory notes using assumptions and market inputs.
Impact: Changes in valuation assumptions can affect liabilities, expenses, and reported equity.
Equity awards require estimates of grant-date fair value and expected award behavior.
Impact: Non-cash compensation increases operating expenses and affects reported loss.
The merger with Semper Merger Sub was treated as a reverse recapitalization because Tevogen Bio was the accounting acquirer.
Impact: Historical financial statements and equity balances are presented as a continuation of Tevogen Bio.
The Warren, New Jersey lease was expanded and extended through February 2033 after operations consolidated there.
Impact: Lease recognition affects assets, liabilities, depreciation, and interest expense.
Similar listed companies
Publicly listed companies with a comparable business focus.
Evogene Ltd.
EVGN · Agricultural Chemicals
Neurogene Inc.
NGNE · Pharmaceutical Preparations
PepGen Inc.
PEPG · Pharmaceutical Preparations
BioVie Inc
BIVI · Pharmaceutical Preparations
Evotec SE
EVO · Pharmaceutical Preparations
Evotec SE is a life science company that provides drug discovery and development services across small molecules, biologics, cell therapies, and related modalities.
Apogee Therapeutics, Inc.
Biological Products, (No Diagnostic Substances)
Last updated: 24/09/2026